SCHEMBL15635609

SCHEMBL15635609

O=Cc1[nH]nc(-c2cccs2)c1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ ALPL P05186 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ADORA2A P29274 1/20 0.39
▸ DPP4 P27487 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ LMNA P02545 2/20 0.36
▸ GSK3A P49840 2/20 0.36
▸ GSK3B P49841 2/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ CASP7 P55210 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500557 0.76 MEN1 (0.44) HSD17B10KDM4EALDH1A1ALPLHPGD
SCHEMBL27781292 0.73 ATM (0.44) HSD17B10KDM4EALDH1A1ALPLHPGD
SCHEMBL1337388 0.68 ERN1 (0.43) HSD17B10KDM4EALDH1A1ALPLHPGD
SCHEMBL3711312 0.68 TTK (0.56) HSD17B10KDM4EALDH1A1ALPLHPGD
SCHEMBL28454459 0.67 RPS6KB2 (0.50) HSD17B10KDM4EALDH1A1HPGDADORA2A
SCHEMBL15635441 0.67 LMNA (0.42) HSD17B10ALDH1A1DPP4MEN1KMT2A
SCHEMBL4923288 0.66 SMN1; SMN2 (0.55) HSD17B10KDM4EALDH1A1HPGDDPP4
SCHEMBL3473292 0.65 RPS6KB2 (0.41) HSD17B10KDM4EALDH1A1HPGDADORA2A
SCHEMBL4291869 0.65 FLT3 (0.60) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL14611730 0.65 HSD17B10 (0.51) HSD17B10KDM4EALDH1A1ALPLHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9260395-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-02-16 — — US disclosed
US-9260395-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-02-16 — — US disclosed
US-9260395-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-02-16 — — US disclosed
US-20150274673-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses HIVIH (FR) 2015-10-01 — — US disclosed
US-20150274673-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses HIVIH (FR) 2015-10-01 — — US disclosed
US-20150274673-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses HIVIH (FR) 2015-10-01 — — US disclosed
EP-2903969-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2015-08-12 — — EP disclosed
WO-2014053665-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2014-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274673-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses RPL35, EIF2AK2, POLRMT HSD17B10 3757/4885KDM4E 1761/4885ALDH1A1 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback